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Levoﬂoxacin was labeled with

99m

Tc using cysteine · HCl as co-ligand and SnCl 2 .2H 2 O as reducing

agent. The inﬂuence of various parameters such as amount of cysteine · HCl, reducing agent, pH value, and
reaction time on labeling process was studied. After optimizing the conditions the labeling was performed
at pH 5 using 1 mg of levoﬂoxacin, 500 μ g of cysteine · HCl, 50 μ g of SnCl 2 .2H 2 O, and 15 min reaction
time. The radiochemical purity was determined with the help of instant thin layer chromatography (ITLC)
and reverse phase high performance liquid chromatography (RP-HPLC) which was more than 95% and was
stable for up to 6 h. Biodistribution of

99m

Tc-levoﬂoxacin ( 99m Tc-lefx) was studied in infection induced

rat models using live Staphylococcus aureus and heat killed S. aureus (sterile inﬂammation model). In the
case of the live S. aureus induced abscess model, the accumulation of
was higher than that of
Key Words: Infection,
∗ Corresponding

99m

Tc-ciproﬂoxacin (

99m

99m

99m

Tc-lefx at target was 3.96, which

Tc-cifx), taken as the control.

Tc-levoﬂoxacin, co-ligand, scintigraphy, biodistribution, infection model

author
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Introduction
In developing countries where the environment, particularly public places, are not fully hygienic, and even in
highly developed countries, bacterial action causes severe infectious diseases associated with morbidity. Early
detection and mapping of the infection site allow prompt and successful treatment. After the development of
radiopharmaceuticals, the risk factors of morbidity associated with infectious diseases sharply decreased.
Radiolabeled pharmaceuticals, for early detection of infections/tumors, should be associated with certain
properties such as ease of labeling, high speciﬁcity, rapid accumulation at the site of infection or tumor, i.e. early
diagnosis, high target to nontarget ratio, rapid blood clearance, low toxicity, low cost, and less antigenicity 1
Due to the easy availability and high compatible half-life of 99m Tc with imaging period of infection foci, 99m Tc
is a more desirable labeling radioisotope as compared to others for diagnostic purposes. 1−3
Certain radiolabeled agents such as 67 Ga-citrate, 4 white blood cells, 5 human immunoglobulin, 6 dextran, 7
and nanocolloid 8 are unable to diﬀerentiate between sterile inﬂammation and septic infection. Quinolones have
been found to be more eﬀective in several types of intracellular infections, 9,10 regardless of the subcellular
localization of the organisms, including those caused by Legionella pneumophila (phagosomes), 11−14 Listeria
monocytogenes (cytosol), or S. aureus (phagolysosomes). 15
Fluoroquinolones speciﬁcally bind and inhibit bacterial DNA gyrase.

Ciproﬂoxacin (Figure 1) is a

ﬂuoroquinolone antibiotic that was ﬁrst labeled using formamidine sulfuric acid (FSA) as
◦

99m

Tc reducing

16

agent at 100 C for 10 min for complexation. Due to the instability of the FSA, stannous ion has been used
to reduce 99m Tc from high oxidation state to a lower one and for increasing labeling yield. Attempts have also
been made to label other antibiotics of the same group with 99m Tc including levoﬂoxacin, 17,18 Norﬂoxacin, 19
Enorﬂoxacin, 20 and Sparﬂoxacin. 21 Levoﬂoxacin (Figure 1), which is a very potent member of the quinolones
family, 9,22,23 having the ability to ﬁght against gram-positive and gram-negative bacteria, is used to treat
infections of the sinuses, skin, lungs, ears, airways, bones, and joints caused by susceptible bacteria. 24

O
N

N

N
N

N

HO

F
O

CH3

HO

F
O

O

A

N

O

B

Figure 1. Structure of A: Levoﬂoxacin, B: Ciproﬂoxacin.

The data obtained about the labeling conditions of 99m Tc with levoﬂoxacin and in vivo study are
preliminary. Extensive research and debate are required to investigate more eﬃcient labeling conditions to label
levoﬂoxacin with 99m Tc. Further, systematic experimentations are also required to chalk out the complete
proﬁle of the eﬃcacy and pharmacokinetics of 99m Tc-lefx against a variety of gram-positive and gram-negative
bacterial strain induced abscess animal models. The whole study may prove that radiolabeled levoﬂoxacin is an
excellent radiopharmaceutical candidate for early detection of chronic infections caused by gram-positive and
gram-negative bacteria.
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The aim of the present study was to standardize and develop a novel method to prepare a stable and
easy to label kit of levoﬂoxacin in a short time and at room temperature and in vivo study in induced abscess
rat models using S. aureus.

Materials and methods
Reagents and equipment
Levoﬂoxacin was purchased from Aventis Ltd (Uxbridge, UK), while Ciproﬂoxacin was from Bayer AG (Wuppertal, Germany). HCl, NaCl, NaHCO 3 , NaOH, and SnCl 2 .2H 2 O were purchased from Aldrich (Germany).
Cysteine· HCl was obtained from MP, USA. All chemicals were of reagent grade and there was no need for
further puriﬁcation prior to use. Sprague-Dawley rats, New Zealand white rabbits, and strains of S. aureus
were obtained from the National Institute of Health (NIH), Islamabad, Pakistan. The animal ethical committee
of the institute gave ethical approval (UHS/Biochemistry/12-162) for the animal study.
from a locally situated ﬁssion based Pakistan Generator (PAKGEN)

99

Mo/

99m

99m

Tc was obtained

Tc generator.

Radiolabeling
To optimize the 99m Tc-labeling conditions, experiments were carried out by dissolving 1 mg of levoﬂoxacin
in 1 mL of distilled water, followed by the addition of varying amounts of cysteine· HCl and SnCl 2 .2H 2 O. To
determine the optimum amount of co-ligand and reducing agent, they were added in varying amounts. The pH
was adjusted by using 0.1 N HCl/NaHCO 3 and NaOH solutions. The radiolabeling was performed by adding
80-1400 MBq of Na 99m TcO 4 /saline, shaking for 30 s, and incubating for 10-30 min. All experiments were
carried out at room temperature and under sterile conditions in a laminar ﬂow hood.

Radiochemical analysis
The radiochemical purity and yield of

99m

Tc-lefx were determined by instant thin layer chromatography

(ITLC) and reverse-phase high performance liquid chromatography (RP-HPLC), using Beckman HPLC systems
consisting of Beckman 125 or 126 solvent-module pump systems with a Beckman 166-NM single wavelength or
168 diode array ultraviolet (UV) detector (Beckman, High Wycombe, UK) and a sodium iodide ﬂow-through
radiochemical detector attached to a Ray test gamma-radioactivity monitor. Acetone or ACN, saline (15% NaCl
solution), or 0.1 M citrate buﬀer (pH 4.5) was used as mobile phase to separate
and reduced/hydrolyzed
the net charge on

99m

99m

99m

Tc-lefx from free

99m

TcO −
4

Tc. The stability of the complex was checked over 6 h at room temperature, while

Tc-lefx was determined by paper electrophoresis.

Paper electrophoresis
The charge on

99m

Tc-lefx was determined by electrophoresis at constant voltage of 10 V/cm for 1 h using

phosphate buﬀer of pH 7.5 and Whatman No. 1 paper as supporting medium. For this 5 μL of

99m

Tc-lefx
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was introduced at the center of the paper impregnated in the phosphate buﬀer. The sample was allowed to run
under the inﬂuence of the voltage for 60 min.

Blood plasma stability
For plasma stability studies, samples of 99m Tc-lefx were incubated at 37 ◦ C with freshly harvested human
blood plasma and aliquots withdrawn at 0, 1, 2, 4, and 24 h time points. Ice-cold acetonitrile (ACN) was added
in a 3:1 (v/v) ACN to aliquot ratio. After centrifugation, supernatant samples were analyzed by ITLC.

Biodistribution study
For biodistribution studies, 200 μL (3 × 10 8 cfu/mL) suspension of S. aureus, ATCC 25923 were injected into
the right ﬂank of Sprague-Dawley rats and grown for 3-5 days; at the end of the infection induced period the
rats were injected with 100 μL of 99m Tc-lefx via the tail vein. At 30 and 60 min and 4 h postinjection, the
animals were anesthetized and dissected. Various organs were removed, washed with saline, dried over ﬁlter
paper, weighed, and counted for radioactivity uptake using a well-type NaI(TI) gamma counter. For imaging
studies, 300 μL of suspension of viable S. aureus was injected into 4 rabbits in their right ﬂank muscles and
imaged at 30 and 60 min and 4 h postinjection. The images were taken using a SPECT (single-photon emission
computed tomography) animal scanner (Bioscan).

Results and discussion
Radiolabeling
Levoﬂoxacin was labeled with 99m Tc under various conditions and the labeling yield was optimized. The
labeling yield was highly dependent on labeling conditions. In order to obtain the optimum concentration of
each reagent for stable and eﬃcient labeling, the pH value was chosen by hit and trial method and pH 5 was
selected for labeling levoﬂoxacin prior to checking the eﬀect of pH on labeling. The highest labeling yield
obtained was >96%, analyzed with the help of ITLC and RP-HPLC (Figure 2). The yield was also calculated
and conﬁrmed by passing the reaction mixture through a 0.22 mm ﬁlter 18 and ITLC analysis using the following
expressions:
%colloid =

Activity before ﬁltration – Activity after ﬁltration
× 100
Activity before ﬁltration

%free pertechnetate (99mT cO4− ) =

Activity at R7 0.75 to 1.0
× 100
Total Activity

%99mTc-lefx = 100 − (%colloid + %99mTcO−
4)

Eﬀect of reducing agent on labeling
To set the optimum amount of reducing agent (SnCl 2 .2H 2 O) and to see its eﬀect on labeling, it was used in
the range of 15 μg to 300 μg. At the initial concentration of reducing agent the labeling eﬃciency was very
poor (∼56%); however, labeling eﬃciency was increased to about 96% at 50 μg/mL of SnCl 2 .2H 2 O (Figure 3).
This showed the lowest concentration of SnCl 2 .2H 2 O that reduced maximum amount of
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maximum labeling yield. Less than this concentration of SnCl 2 .2H 2 O failed to reduce whole of the
for the labeling process.

Figure 2. HPLC analysis of

99m

99m

TcO −
4

Tc-lefx; the main peaks elute at 12.89 min showing > 95% labeling yield.
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Figure 3. Eﬀect of reducing agents (SnCl 2 .2H 2 O) on

Figure 4. Eﬀect of cysteine · HCl (Co-ligand) on labeling

labeling eﬃciency.

eﬃciency.

Eﬀect of cysteine·HCl
Cysteine· HCl was used as co-ligand to reduce the reaction time and impart labeling stability to

99m

Tc-lefx.

Concentration optimization of cysteine· HCl was carried out by studying various amounts of it (0-3.0 mg) in the
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labeling process. The maximum labeling yield, 95.6%, was achieved using 500 μg of cysteine· HCl/mL (Figure
4). This fact can probably be ascribed to the ligand exchange method, whereby cysteine· HCl is labeled rapidly
with a reduced form of 99m Tc, resulting in an exchange of metal from cysteine· HCl to the levoﬂoxacin molecule
with long incubation times. This results in increased complex stability and radiolabeling eﬃciency.

Eﬀect of pH
To establish the role of pH in radiolabeling, diﬀerent pH conditions were studied. Acidic pH showed no prominent
diﬀerence in labeling yield, whereas near basic pH the labeling eﬃciency was decreased, as shown in Figure 5.
This may be attributed to a change in the structure of the levoﬂoxacin in basic medium. The carboxylic moiety
of levoﬂoxacin may be neutralized, making it unable to make a complex with 99m Tc during the metal exchange
reaction process. The most favorable pH value that gave stable labeling was 5. Beyond this value the labeling
eﬃciency and stability began to decrease.
110

%age Labeling

100

90

80

70

60
2

3

4

5

6

7

pH

Figure 5. Eﬀect of pH on labeling eﬃciency.

Incubation eﬀect on labeling
Incubation period reveals the completion of the reaction and time of maximum yield of the radiolabeled
compound. It was observed that optimal radiolabeling (>95%) was obtained at 15 min incubation period.
Incubation for longer time intervals did not show any remarkable change. The stability of the labeled levoﬂoxacin
up to 6 h also showed >94% intact complex, as shown in Table 1.

Optimum parameters for levoﬂoxacin kit formulation and radiolabeling
After setting the optimum conditions of diﬀerent parameters, the following appropriate conditions were chosen
for preparing the levoﬂoxacin kit: 1 mg of levoﬂoxacin, 500 μg of cysteine· HCl, and 2 mg of gentistic acid;
all these ingredients were dissolved in 800 μL of distilled water and 50 μg of SnCl 2 .2H 2 O was added. The
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pH of the resulting solution was adjusted to 5 with 0.1 N NaOH, and monitored for 15 min with continuous
r GV Filter Unit, Ireland).
stirring. This prepared kit was then ﬁltered through a 0.22 μm ﬁlter (MILLEX
◦
After lyophilization the freeze dried kits were stored at 4 C. The whole process was carried out under sterile
conditions and at room temperature. The kit was labeled with 80-1400 MBq
chromatography, (ITLC) and RP-HPLC, for further tests.
Table 1. Stability study of

Time (hours)

99m

% Radioligand

99m

Tc and analyzed using paper

Tc-lefx kit up to 6 h.

% Colloid 99m TcO−
4

15 min

95.95 ± 4.65

3.03 ± 2.08

0.5

96.02 ± 5.43

2.95 ± 1.80

1

95.12 ± 6.33

3.89 ± 2.01

2

95.88 ± 4.83

3.08 ± 1.70

3

95.66 ± 7.67

3.99 ± 1.98

4

95.47 ± 6.96

3.56 ± 2.43

5

95.12 ± 5.97

3.34 ± 2.06

6

94.71 ± 7.09

4.25 ± 3.08

Paper electrophoresis
Apparent charge on the radiolabeled molecule may change its biological interaction in the living system. This
increases or decreases the binding potential of the bioactive molecule with the cell membrane. Apparent charge
on the

99m

Tc-lefx was determined by paper electrophoresis. The experiments revealed that

no charge and it had a neutral moiety. Only a small amount of free pertechnetate (

99m

99m

TcO −
4 )

Tc-lefx carried

was moved along

99m

with solvent front and all the activity (
Tc-lefx) remained at the baseline. A trace amount of colloid also
appeared near the baseline due to the very small electrical charge on the colloid material. The colloid formed
due to hydrolysis of tin (Sn +2 ) and reduced 99m Tc diminished the yield of 99m Tc labeled levoﬂoxacin. Total
colloid %age was <1.4% in each labeling reaction, which was very poor, resulting in excellent % yield of labeled
levoﬂoxacin.

Human blood plasma stability
No signiﬁcant diﬀerences in the serum stability of the radiolabeled levoﬂoxacin were observed, with more than
90% of 99m Tc-lefx remaining intact after 2 h of incubation in human serum. After 24 h only 18% 99m Tc-lefx
was degraded. This indicated that the blood serum enzymes were unable to degrade the 99m Tc-lefx within ﬁrst
half-life of 99m Tc and 99m Tc-lefx can bind with bacterial DNA gyrase before blood protease degradation.

In vivo study
Complex stability of 99m Tc-lefx and in vivo behavior were ﬁnally assessed in a S. aureus infection induced animal
model. The biodistribution in infection-bearing rats was studied by radioactivity counting using a well-typed
NaI(TI) gamma counter. Radioactivity was counted immediately after dissecting and washing at subsequent
273

99m

Tc labeled levoﬂoxacin as an infection imaging agent: a novel..., S. A. R. NAQVI, et al.

time points up to 4 h. The results of biodistribution studies of 99m Tc-lefx and 99m Tc-cifx are summarized in
Table 2. Following the 80 MBq of 99m Tc-lefx in live S. aureus and heat killed S. aureus infected/inﬂamed rats,
the maximal uptake was seen in the kidney and liver, which decreases with time. Uptake of activity appeared
in both infected and inﬂamed foci at early time points (30 min and 1 h postinjection), whereas at 4 h only the
infected focus showed prominent uptake. The activity uptake at the infected site in the case of both labeled
antibiotics showed considerable diﬀerence, as it was 0.96%, 3.96%, and 2.18% of 99m Tc-lefx and 0.76%, 2.71%,
and 1.83% of 99m Tc-cifx at 30 min, 1 h, and 4 h postinjection, respectively.
Table 2. (a) Biodistribution of
of

99m

99m

Tc-lefx in live S. aureus and heat killed S. aureus infected rats. (b) Biodistribution

Tc-cifx in live S. aureus and heat killed S. aureus infected rats.

(a)
After 30 min

After 1 h

After 4 h

Organs

Live
bacterial
abscess

Killed
bacterial
abscess

Live
bacterial
abscess

Killed
bacterial
abscess

Live
bacterial
abscess

Killed
bacterial
abscess

Infected muscle

0.96 ± 0.09

0.51 ± 0.06

3.96 ± 1.79

1.35 ± 1.05

2.18 ± 1.57

0.69 ± 0.78

Normal muscle

0.20 ± 0.00

0.24 ± 0.01

0.23 ± 0.

0.22 ± 0.03

0.19 ± 0.

0.18 ± 0.00

Liver

3.01 ± 2.30

3.03 ± 1.79

2.09 ± 1.3

2.93 ± 1.62

0.41 ± 0.7

0.52 ± 0.54

Spleen

0.23 ± 0.01

0.26 ± 0.00

0.25 ± 0.00

0.30 ± 0.03

0.15 ± 0.

0.17 ± 0.04

Lungs

0.82 ± 0.01

0.87 ± 0.09

0.50 ± 0.

0.54 ± 0.02

0.29 ± 0.

0.36 ± 0.03

Stomach

0.75 ± 0.10

0.80 ± 0.01

0.37 ± 0.01

0.33 ± 0.03

0.41 ± 0.

0.52 ± 0.08

Kidney

15.10 ± 4.91

22.33 ± 4.99

17.04 ± 3.60

19.12 ± 3.05

10.64 ± 3.25

6.14 ± 2.88

Blood

0.35 ± 0.08

0.56 ± 0.14

0.51 ± 0.6

0.48 ± 0.13

0.26 ± 0.07

0.21 ± 0.10

Heart

0.43 ± 0.02

0.37 ± 0.00

0.63 ± 0.00

0.58 ± 0.03

0.16 ± 0.

0.14 ± 0.00

(b)

Organs

After 30 min
Live
Killed
bacterial
abscess

After 1 h

After 4 h

Live

Killed

Live

Killed

bacterial
abscess

bacterial
abscess

bacterial
abscess

bacterial
abscess

bacterial
abscess

Infected muscle

0.76 ± 0.02

0.59 ± 0.01

2.71 ± 1.87

1.41 ± 1.09

1.83 ± 1.30

0.83 ± 0.77

Normal muscle

0.20 ± 0.00

0.17 ± 0.00

0.23 ± 0.01

0.20 ± 0.00

0.21 ± 0.01

0.19 ± 0.07

Liver

7.59 ± 3.89

7.13 ± 2.31

3.31 ± 2.12

4.13 ± 2.56

0.83 ± 0.26

0.77 ± 0.09

Spleen

0.48 ± 0.00

0.42 ± 0.02

0.23 ± 0.00

0.29 ± 0.01

0.22 ± 0.00

0.31± 0.02

Lungs

0.86 ± 0.01

0.79 ± 0.07

0.46 ± 0.02

0.51 ± 0.05

0.24 ± 0.

0.29 ± 0.00

Stomach

0.89 ± 0.00

0.95 ± 0.14

0.39 ± 0.04

0.32 ± 0.01

0.32 ± 0.09

0.35 ± 0.12

Kidney

19.82 ± 4.01

19.42 ± 3.04

18.04 ± 3.44

20.12 ± 4.26

12.13 ± 3.05

05.22 ± 2.66

Blood

0.23 ± 0.01

0.38 ± 0.07

0.23 ± 0.8

0.31 ± 0.09

0.24 ± 0.10

0.18 ± 0.03

Heart

0.98 ± 0.01

0.88 ± 0.07

0.63 ± 0.06

0.58 ± 0.09

0.21 ± 0.00

0.23 ± 0.01
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In previous studies, 17,18 E. coli infection induced animal models were used to assess the in vivo behavior of
the labeled levoﬂoxacin. EL-Ghany et al. 18 reported data about the labeling of levoﬂoxacin and biodistribution
in E. coli induced abscess animal models. The maximum activity that accumulated at the site of infection focus
in the live E. coli model was 2.9%, while in the heat killed E. coli model it was 2.0%.
In the present study, 99m Tc-lefx accumulates much more in the live S. aureus induced infection model
(3.96%) than in the sterile inﬂammation dead model. The 99m Tc-lefx complex appears to be more susceptible
for S. aureus induced abscess as compared to the E. coli model. 18 To the best of our knowledge no study has
previously been reported on the study of 99m Tc labeled levoﬂoxacin using S. aureus induced abscess. A study
to further analyze the eﬃcacy and stability of 99m Tc-lefx using our novel labeling method is being conducted
in patients with chronic infections caused by S. aureus/E. coli. Uptake at the infection focus in the initial
scintigraphic study of 30 min postinjection in an infection induced rabbit model indicates
at the site of infection and stability of the complex (Figure 6).

Figure 6. Scintigraphic study of rabbits using

99m

99m

Tc-lefx binding

Tc-lefx at 30 min postinjection showing radioactivity uptake at

infection site.
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Conclusion
Labeled compounds have directed medical researchers toward easy and quick diagnostic strategies for infection
and tumors. Of these, labeled antibiotics are particularly important in the diagnosis of infectious foci and to
distinguish such foci from sterile inﬂammation.
Comparing the methods of labeling levoﬂoxacin with 99m Tc, as reported previously, labeling in the
presence of co-ligand cysteine· HCl and reducing agent SnCl 2 .2H 2 O is quick, stable, and eﬃcient. All the data
gathered show very good results and may further be used in clinical tests to diagnose sinus, skin, lungs, ear,
airways, bone, and joint infections caused by susceptible bacteria.
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